Teva Pharmaceutical Industries vs Universe Pharmaceuticals
TEVA and UPC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TEVA and UPC compare
Teva Pharmaceutical Industries grew revenue faster over the last twelve months (−15.2% versus −22.4% for Universe Pharmaceuticals).
Teva Pharmaceutical Industries keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with −20.6% at Universe Pharmaceuticals.
Teva Pharmaceutical Industries scores higher on the StockData Score (7 against 5 for Universe Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TEVA | UPC |
|---|---|---|
| Size and price | ||
| Market cap | $50.9B | – |
| Share price | $43.65 | $1.51 |
| Change, 1 year | 73.7% | −59.0% |
| Change, 5 years | 392% | −100.0% |
| Beta (5Y) | 0.98 | 1.06 |
| Employees | 34K | 225 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 72.8× | – |
| P/S | 3.6× | – |
| P/B | 6.6× | – |
| EV/EBITDA | 20.0× | – |
| P/FCF | 37.7× | – |
| FCF yield | 2.7% | – |
| Fair value | $19.90 | – |
| Margin of safety | −119% | – |
| Growth | ||
| Revenue growth (TTM) | −15.2% (better) | −22.4% |
| Revenue growth, 5Y average | 0.71% | 257% (better) |
| Profitability | ||
| Gross margin | 64.4% (better) | 35.3% |
| Operating margin | 11.4% (better) | −16.3% |
| Net margin | 5.0% (better) | −20.6% |
| FCF margin | 9.6% (better) | −29.8% |
| Return on equity | 9.7% (better) | −7261% |
| Return on invested capital | 23.0% (better) | −78.0% |
| Financial health | ||
| Debt / equity | 0.58 | 0.13 (better) |
| Net debt / EBITDA | 0.33 | – |
| Interest coverage | – | −10.1× |
| Current ratio | 0.88 | 4.05 (better) |
| Altman Z-score | 0.89 | – |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | – | 6.6% |
| Held by insiders | 0.41% | – |
| Insider net buying, 12 months | −$124M | – |
| Short interest, % of float | 2.4% | – |
Go deeper
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
- UPC stock overview
- UPC income statement
- UPC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.